Day: September 3, 2024

Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million

Written by Customer Service on September 3, 2024. Posted in Mergers And Acquisitions.

Oruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and other associated conditions Company on track to advance co-lead programs, ORKA-001 and ORKA-002, into the clinic and show initial pharmacokinetic data for ORKA-001 next year Samarth Kulkarni, PhD, appointed Chairman of Oruka’s Board of Directors Shares to trade on Nasdaq under the ticker symbol “ORKA” commencing today, September 3, 2024 MENLO PARK, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced the completion of its previously announced merger with ARCA biopharma, Inc....

Troilus Drills 20m Grading 1.66 g/t AuEq in New Gold Zone ‘West Rim’ and Identifies Further Near-Surface High-Grade Targets

Written by Customer Service on September 3, 2024. Posted in Earnings Releases And Operating Results.

MONTREAL, Sept. 03, 2024 (GLOBE NEWSWIRE) — Troilus Gold Corp. (“Troilus” or the “Company”, TSX: TLG; OTCQX: CHXMF; FSE: CM5R) is pleased to announce positive drill results forming part of a 1,866-metre exploratory drill program on its newly discovered “West Rim” VMS (Volcanogenic massive sulfide ore deposit) target, located within 150 metres of the North Reserve Pit Shell (Zones 87, J & X22) (see Figure 1) at its Troilus Project, located in northcentral Quebec, Canada. The West Rim drill program was designed to test various geophysical anomalies and collect geological data that will inform the next phase of drilling. West Rim Highlights:WR-24-003 returned 1.66 g/t AuEq (1.64 g/t Au, 0.92 g/t Ag, 0.01% Cu) over 20m including 3.10 g/t AuEq (3.07 g/t Au, 1.62 g/t Ag, 0.01 % Cu) over 8m starting at 87 m downhole (See Figures...

Americold Realty Trust, Inc. Declares Third Quarter 2024 Dividend

Written by Customer Service on September 3, 2024. Posted in Dividend Reports And Estimates.

ATLANTA, GA., Sept. 03, 2024 (GLOBE NEWSWIRE) — Americold Realty Trust (NYSE: COLD), a global leader in temperature-controlled logistics, real estate, and value-added services focused on the ownership, operation, acquisition and development of temperature-controlled warehouses, today announced that its Board of Directors has declared a dividend of $0.22 per share for the third quarter of 2024, payable to holders of the Company’s common stock. The dividend will be payable in cash on October 15, 2024 to stockholders of record at the close of business on September 30, 2024. About Americold Realty Trust, Inc. Americold is a global leader in temperature-controlled logistics real estate and value added services. Focused on the ownership, operation, acquisition and development of temperature-controlled warehouses, Americold owns and/or...

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Written by Customer Service on September 3, 2024. Posted in Public Companies.

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, Chief Executive Officer, will participate in a fireside chat and investor one-on-ones at the upcoming H.C. Wainwright 26th Annual Global Investment Conference on September 9-11th. The fireside chat will take place at 7:00 a.m. ET on Monday, September 9th. To access this event, please register at https://journey.ct.events/view/ad5300ce-fb6d-41fc-a276-ec783460f6d9. Following the event, a replay of the fireside chat will be posted to MiNK’s website at https://investor.minktherapeutics.com/events-and-presentations. About MiNK...

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

Written by Customer Service on September 3, 2024. Posted in Public Companies.

JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of preclinical data for the company’s novel oral C5aR inhibitor, INF904, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) being held in Lübeck, Germany, September 2 – 6, 2024. Members of InflaRx leadership also participated in a satellite symposium highlighting the role of the C5a/C5aR1 axis in driving inflammation and served as the biopharma industry representative on a panel focused on the relevance of targeting C3 and C5. InflaRx also hosted a lunch seminar focused on C5a/C5aR inhibition in human disease with best-in-class compounds. Camilla Chong, MD, Chief Medical Officer of InflaRx, commented:...

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

Written by Customer Service on September 3, 2024. Posted in Public Companies.

PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company’s president and CEO, Lisa Ricciardi will participate in two investor conferences in September. September 2024 Investor Conferences Event: Chardan Capital Markets Leadership Call Date/Time: September 5, 2024, at 11:00am ETLivestream: Individuals interested in attending the live virtual event can email corpaccess@chardan.com Event: H.C. Wainwright 26th Annual Global Investment Conference Date/Time: September 9-11, 2024 Webcast: Available On-Demand beginning September 9th at 7:00am ET “We recently presented results from the Phase 2, proof-of-concept, SHINE study showing our orally delivered CT1812...

Invesco Ltd: Form 8.3 -Rightmove PLC; Opening Position Disclosure

Written by Customer Service on September 3, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 OPENING POSITION DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION (a) Full name of discloser: Invesco Ltd. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree Rightmove PLC (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:For an opening position disclosure, state the latest practicable date prior to...

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

Written by Customer Service on September 3, 2024. Posted in Earnings Releases And Operating Results.

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label extension phase in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy adult subjects approved in the UK and recruiting Cash, cash equivalents, other financial assets and marketable securities of $204.5 millionDUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2024, and provided updates on its business. Business Updates We announced today, in a separate press release, the promotion...

Auddia Announces Integration of faidr Into Apple CarPlay and Android Auto

Written by Customer Service on September 3, 2024. Posted in Public Companies.

BOULDER, CO, Sept. 03, 2024 (GLOBE NEWSWIRE) — More Than 90% of New Vehicles Now Offer Apple CarPlay or Android Auto and Will Have Access to faidr’s AI Technology When Apple CarPlay or Android Auto are Available More Than 50% of All Audio Listening is to AM/FM and Podcasts {{DATELINECITY_DATE_GLOBENEWSWIRE_BUG} Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) (“Auddia” or the “Company”), a proprietary AI platform for audio identification and classification and related technologies, reinventing how consumers engage with AM/FM radio, podcasts, and other audio content, today announced it recently launched both Apple CarPlay and Android Auto interfaces for its faidr mobile application. These interfaces allow consumers to mirror their smartphone entertainment options on the screen of their vehicle’s infotainment system. Apple CarPlay and...

The Ensign Group Adds Seven New Operations in Colorado

Written by Customer Service on September 3, 2024. Posted in Mergers And Acquisitions.

SAN JUAN CAPISTRANO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it acquired the operations of the following skilled nursing facilities in Colorado:Desert Willow Health and Rehabilitation Center, a 106-bed skilled nursing facility located in Pueblo, Colorado; Junction Creek Health and Rehabilitation Center, a 133-bed skilled nursing facility located in Durango, Colorado; Pelican Pointe Health and Rehabilitation Center, a 104-bed skilled nursing facility located in Windsor, Colorado; Riverbend Health and Rehabilitation Center, a 100-bed...

Day: September 3, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice